 |
|
|
||||||||||||||
 |
|
|
Tethys is dedicated to the discovery of novel multi-biomarker assays that identify individuals at highest risk for devastating diseases, such as diabetes. The goal of the Company is to provide new clinical practice tools that will help physicians and patients delay or prevent cardiometabolic disease and events.
We realize that our efforts will be enhanced by joining with strategic partners with shared interests in the cardiometabolic therapeutic arena and with a commitment to bettering the lives of individuals at risk for these diseases.
Tethys seeks partnerships with companies and organizations with aligned business objectives, shared customer base, synergistic and complementary capabilities and a willingness to engage in collaborative partnerships that can extend our respective corporate reaches.
Please send inquiries to partners@tethysbio.com
All information submitted is governed by our Privacy Policy.
Aug 25, 2008
Beyond Single-marker Diabetes Detection: The Evolution of Diabetes Risk Assessment
(New CME Program)
Jul 2, 2008
Tethys unveils advanced-warning test for diabetes by Michael Fitzhugh
(East -Bay Business Times Friday, June 13, 2008)
Jul 2, 2008
A Predictive Tool for Diabetes By Thomas Goetz
(Epidemix.org)
Jun 9, 2008
Diabetes test gives 5-year disease-prediction window.
"There is an old saying that seems appropriate when describing Tethys Bioscience's PreDx Diabetes Risk Test: Forewarned is forearmed. The company presented clinical results of the test and reported expanding the test's availability during the American Diabetes Associations's annual meeting in San Francisco this past week." Full text.
Jun 7, 2008
Tethys Bioscience Announces Expanded Availability of PreDx™ Diabetes Risk Test
A Powerful New Tool for Early Identification of High Risk Patients
Early Intervention Can Help Prevent Disease Progression